
USD
+$0.00
(+0.00%
)At Close (As of Oct 23, 2025)
$21.82B
Market Cap
-
P/E Ratio
-0.15
EPS
$22.80
52 Week High
$12.47
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $8.1B |
| Total Revenue | $17B |
| Cost Of Revenue | $8.5B |
| Costof Goods And Services Sold | $8.5B |
| Operating Income | -$303M |
| Selling General And Administrative | $1.2B |
| Research And Development | $998M |
| Operating Expenses | $8.4B |
| Investment Income Net | - |
| Net Interest Income | -$1.1B |
| Interest Income | - |
| Interest Expense | $1B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1B |
| Income Before Tax | -$1.3B |
| Income Tax Expense | $676M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$282M |
| Ebitda | $777M |
| Net Income | -$1.6B |
| Field | Value (USD) |
|---|---|
| Total Assets | $39B |
| Total Current Assets | $13B |
| Cash And Cash Equivalents At Carrying Value | $3.3B |
| Cash And Short Term Investments | $3.3B |
| Inventory | $3B |
| Current Net Receivables | $3.1B |
| Total Non Current Assets | $27B |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $4.4B |
| Intangible Assets Excluding Goodwill | $4.4B |
| Goodwill | $15B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $3.2B |
| Other Non Current Assets | - |
| Total Liabilities | $34B |
| Total Current Liabilities | $13B |
| Current Accounts Payable | $2.2B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.8B |
| Total Non Current Liabilities | $21B |
| Capital Lease Obligations | $296M |
| Long Term Debt | $16B |
| Current Long Term Debt | $1.8B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $18B |
| Other Current Liabilities | $8.8B |
| Other Non Current Liabilities | $4B |
| Total Shareholder Equity | $5.4B |
| Treasury Stock | - |
| Retained Earnings | -$15B |
| Common Stock | $58M |
| Common Stock Shares Outstanding | $1.1B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $1.2B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.1B |
| Capital Expenditures | $498M |
| Change In Receivables | - |
| Change In Inventory | $166M |
| Profit Loss | - |
| Cashflow From Investment | $792M |
| Cashflow From Financing | -$1.8B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$2B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $8.1B |
| Total Revenue | $17B |
| Cost Of Revenue | $8.5B |
| Costof Goods And Services Sold | $8.5B |
| Operating Income | -$303M |
| Selling General And Administrative | $1.2B |
| Research And Development | $998M |
| Operating Expenses | $8.4B |
| Investment Income Net | - |
| Net Interest Income | -$1.1B |
| Interest Income | - |
| Interest Expense | $1B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1B |
| Income Before Tax | -$1.3B |
| Income Tax Expense | $676M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$2B |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$282M |
| Ebitda | $777M |
| Net Income | -$1.6B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2017-11-27 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 0.085 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Teva Pharmaceutical Industries Limited (Ticker: TEVA) is a global leader in the development, manufacturing, and distribution of generic and specialty pharmaceuticals, as well as biopharmaceuticals, with a strong presence in North America, Europe, and beyond. Headquartered in Petach Tikva, Israel, Teva's extensive product portfolio addresses a wide range of therapeutic areas, positioning the company as a pivotal player in the pharmaceutical industry. With a commitment to innovation and accessibility, Teva continues to leverage its scientific expertise and market reach to enhance healthcare outcomes worldwide.